Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
5.525 USD | -0.99% | +0.45% | -46.25% |
Dec. 06 | Novavax: extended authorization for Covid vaccine in Canada | CF |
Dec. 06 | Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil... | ![]() |
Financials (USD)
Sales 2023 * | 1.01B | Sales 2024 * | 1.05B | Capitalization | 657M |
---|---|---|---|---|---|
Net income 2023 * | -402M | Net income 2024 * | -85M | EV / Sales 2023 * | -0,07x |
Net cash position 2023 * | 733M | Net cash position 2024 * | 422M | EV / Sales 2024 * | 0,22x |
P/E ratio 2023 * | -1,35x | P/E ratio 2024 * | -6,85x | Employees | 1,992 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 93.49% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.90% | ||
1 week | +0.55% | ||
Current month | +0.55% | ||
1 month | -22.00% | ||
3 months | -39.56% | ||
6 months | -27.90% | ||
Current year | -46.21% |
1 week
5.42
6.05

1 month
5.30
7.49

Current year
5.30
13.70

1 year
5.30
18.55

3 years
5.30
331.68

5 years
3.54
331.68

10 years
3.54
331.68

Managers | Title | Age | Since |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 56 | Jan. 22 |
John Trizzino
PSD | President | 63 | 2014 |
James Kelly
DFI | Director of Finance/CFO | 57 | 2021 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 56 | 2022 |
Gregg Alton
BRD | Director/Board Member | 57 | 2020 |
David Mott
BRD | Director/Board Member | 57 | 2020 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 12 M€ | -19.86% | ||
1.29% | 19 M€ | +0.70% | ||
1.27% | 4,878 M€ | -2.99% | ||
1.27% | 3 M€ | -9.57% | ||
1.10% | 8 M€ | -15.04% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-07 | 5.53 | -0.90% | 5,705,634 |
23-12-06 | 5.58 | -0.18% | 5,970,708 |
23-12-05 | 5.59 | -2.78% | 8,146,744 |
23-12-04 | 5.75 | +3.23% | 6,231,702 |
23-12-01 | 5.57 | +1.27% | 6,867,930 |
Delayed Quote Nasdaq, December 07, 2023 at 03:59 pm EST
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
Calendar
2024-02-26
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.53USD
Average target price
19.6USD
Spread / Average Target
+254.43%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.21% | 657 M $ | |
+69.89% | 41 191 M $ | |
+4.93% | 39 236 M $ | |
-55.49% | 30 484 M $ | |
-27.50% | 27 837 M $ | |
+38.06% | 22 079 M $ | |
-25.41% | 22 245 M $ | |
-1.81% | 16 633 M $ | |
-12.95% | 11 376 M $ | |
-17.89% | 10 762 M $ |